ReviewThe American journal of gastroenterology2026
Budd-Chiari Syndrome: Presentation, Management, and Prognosis.
Review in The American journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical applications of 4D flow magnetic resonance imaging in hepatic vascular disorders: practical biomarkers, protocol design, and translational implementation.Quantitative imaging in medicine and surgery · 2026Review
- Case report: Emergency management of adjacent arterial injury during inferior vena cava angioplasty in a patient with Budd-Chiari syndrome.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Budd-Chiari syndrome (BCS) is a rare condition characterized by hepatic vein obstruction causing liver congestion, dysfunction, and rarely liver failure. BCS may present as acute, subacute, or chronic liver disease. It usually presents at a younger age as compared with other splanchnic thrombotic conditions. Prothrombotic conditions, myeloproliferative disorders, and oral contraceptives use are common risk factors. In addition, lower socioeconomic status and malnutrition are associated with BCS. Many prognostic scores are available, and they are useful for general guidance. A stepwise treatment strategy is recommended for the management of BCS, starting with anticoagulation followed by portosystemic shunting and liver transplantation for most patients with BCS, but such a strategy may not be applicable in those who present with acute liver failure. Post liver transplant survival outcomes in BCS, including in those who present with acute liver failure and multiple organ failures, are comparable with other indications. Pregnancy is not contraindicated in those with BCS, and maternal outcomes are favorable, but fetal outcomes remain poor. Most patients with BCS, including those who had liver transplantation, require lifelong anticoagulation. There are limited data on chronic BCS, and these patients are often diagnosed with complications of portal hypertension or liver cancer. In this review, we discuss our current understanding of etiologies, diagnostic options and prognostic scores, natural history including pregnancy outcomes, and treatment outcomes of BCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.